---
title: "GSK Board Members Increase Stake in Company"
description: "GSK plc announced that several board members, including Sir Jonathan Symonds and Wendy Becker, purchased shares on March 20, 2025. This acquisition of Ordinary Shares and American Depositary Shares re"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/232773372.md"
published_at: "2025-03-21T15:37:41.000Z"
---

# GSK Board Members Increase Stake in Company

> GSK plc announced that several board members, including Sir Jonathan Symonds and Wendy Becker, purchased shares on March 20, 2025. This acquisition of Ordinary Shares and American Depositary Shares reflects their confidence in the company's future and may positively influence investor perception. GSK is a global healthcare company focused on pharmaceuticals, vaccines, and consumer healthcare products, with a current market cap of £62.34B and a year-to-date price performance of 13.03%.

An announcement from GlaxoSmithKline ( (GB:GSK) ) is now available.

GSK plc announced transactions involving the purchase of shares by several of its board members, including Sir Jonathan Symonds, Wendy Becker, Elizabeth McKee Anderson, Charles Bancroft, Dr Hal Barron, Dr Anne Beal, Dr Hal Dietz, and Dr Jesse Goodman. These transactions, conducted on March 20, 2025, involved the acquisition of both Ordinary Shares on the London Stock Exchange and American Depositary Shares on the New York Stock Exchange. The purchases reflect confidence in the company’s future prospects and may influence investor perception positively.

**More about GlaxoSmithKline**

GSK plc, also known as GlaxoSmithKline, is a global healthcare company that operates in the pharmaceutical industry. It focuses on the development and manufacturing of medicines, vaccines, and consumer healthcare products, serving markets worldwide.

**YTD Price Performance:** 13.03%

**Average Trading Volume:** 8,323,003

**Technical Sentiment Consensus Rating:** Strong Sell

**Current Market Cap:** £62.34B

Learn more about GSK stock on TipRanks’ Stock Analysis page.

## Trending Articles:

-   NVO Lawsuit Alert! Class Action Lawsuit Against Novo Nordisk A/S
-   Micron Stock Remains Attractive with Strong AI Demand, Says Mizuho and Hikes PT
-   Nvidia Ventures into the Quantum Computing Space with New Lab in Boston

Questions or Comments about the article? Write to editor@tipranks.com

### Related Stocks

- [GSK.US - GSK](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.UK - GlaxoSmithKline plc](https://longbridge.com/en/quote/GSK.UK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 葛兰素史克获得欧洲委员会对 Exdensur 的批准 | 葛兰素史克：葛兰素史克 - 欧洲委员会批准的 EXDENSUR | [Link](https://longbridge.com/en/news/276102835.md) |
| 葛兰素史克启动最多达 4.5 亿英镑的股票回购批次 | 葛兰素史克启动高达 4.5 亿英镑的股票回购计划 | [Link](https://longbridge.com/en/news/276103252.md) |
| Madrigal 制药｜8-K：2025 财年 Q4 营收 3.21 亿美元超过预期 |  | [Link](https://longbridge.com/en/news/276330350.md) |
| 贝伦贝格银行维持对葛兰素史克（GSK）的持有评级 | Berenberg Bank 分析师 Kerry Holford 对葛兰素史克 (GSK) 维持了持有评级，目标价为 20.00 英镑。Holford 专注于医疗保健行业，推荐股票的平均回报率为 9.7%，成功率为 59.14%。此外，美国 | [Link](https://longbridge.com/en/news/276103203.md) |
| 美股盘中速递：医疗保健行业波动加剧，Dermata Therapeutics 股价暴跌 24.87%！分析师评级引发市场担忧 | Dermata Therapeutics 跌 24.87%；GRAIL 跌 45.71%，成交额达到 4.01 亿美元；艾伯维跌 0.22%，成交额达到 2.75 亿美元；安进跌 0.28%，成交额达到 2.18 亿美元；吉利德科学涨 0. | [Link](https://longbridge.com/en/news/276461704.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.